AchillesLatest News

Achilles Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

28/11/2019

Stevenage, UK 28 November 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announced that Dr. Iraj Ali,...

Read More +

Achilles Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

14/11/2019

Stevenage, UK 14 November 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announced that Dr. Iraj...

Read More +

Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer – Brings 20+ years of business development experience – Formerly VP, Business Development for the Immuno-inflammation Therapy Area at GSK

21/10/2019

Stevenage, UK 21 October 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces it has appointed...

Read More +

ACHILLES THERAPEUTICS RAISES £100 MILLION IN OVERSUBSCRIBED SERIES B FINANCING

03/09/2019

– Leading international syndicate led by RA Capital and cornerstoned by founding investor Syncona – Confirms depth of support for clonal...

Read More +

ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN METASTIC OR RECURRENT MELANOMA – Second CTA approval in 2019 – the first was for a NSCLC study

13/02/2019

Stevenage, UK 13 February 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the approval by...

Read More +

ACHILLES THERAPEUTICS APPOINTS DR MARKUS DANGL AS CHIEF SCIENTIFIC OFFICER

12/02/2019

Stevenage, UK 12 February 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the appointment of...

Read More +

ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN NON-SMALL CELL LUNG CANCER – Ground-breaking clinical trial in patients with significant unmet medical need to start this year

21/01/2019

Stevenage, UK 21 January 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical...

Read More +

ACHILLES THERAPEUTICS APPOINTS DR EDWIN MOSES AS CHAIRMAN OF ITS BOARD OF DIRECTORS AND DR IRAJ ALI AS CHIEF EXECUTIVE OFFICER

10/12/2018

Stevenage, UK; 10 December 2018 – Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer...

Read More +

ACHILLES TODAY ANNOUNCES THAT IT HAS APPOINTED SENIOR PHARMACEUTICAL EXECUTIVE MICHAEL F. GIORDANO, M.D., TO ITS BOARD OF DIRECTORS.

19/09/2018

Stevenage, 19 September 2018 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens, today announced that it...

Read More +